Format
Items per page
Sort by

Send to:

Choose Destination

Results: 18

Cited In for PubMed (Select 15923465)

1.

Perceived harm of tobacco products and individual schemas of a smoker in relation to change in tobacco product use over one year among young adults.

Berg CJ, Romero DR, Pulvers K.

Subst Use Misuse. 2015 Jan;50(1):90-8. doi: 10.3109/10826084.2014.958858. Epub 2014 Oct 22.

2.

Perceived harm, addictiveness, and social acceptability of tobacco products and marijuana among young adults: marijuana, hookah, and electronic cigarettes win.

Berg CJ, Stratton E, Schauer GL, Lewis M, Wang Y, Windle M, Kegler M.

Subst Use Misuse. 2015 Jan;50(1):79-89. doi: 10.3109/10826084.2014.958857. Epub 2014 Sep 30.

3.

In and across bureaucracy: structural and administrative issues for the tobacco endgame.

Isett KR.

Tob Control. 2013 May;22 Suppl 1:i58-60. doi: 10.1136/tobaccocontrol-2012-050828.

4.

Dose-response effects of spectrum research cigarettes.

Hatsukami DK, Heishman SJ, Vogel RI, Denlinger RL, Roper-Batker AN, Mackowick KM, Jensen J, Murphy SE, Thomas BF, Donny E.

Nicotine Tob Res. 2013 Jun;15(6):1113-21. doi: 10.1093/ntr/nts247. Epub 2012 Nov 22.

5.

Nicotine reduction: strategic research plan.

Hatsukami DK, Benowitz NL, Donny E, Henningfield J, Zeller M.

Nicotine Tob Res. 2013 Jun;15(6):1003-13. doi: 10.1093/ntr/nts214. Epub 2012 Oct 25. Review.

6.

Research required for the effective implementation of the framework convention on tobacco control, articles 9 and 10.

Gray N, Borland R.

Nicotine Tob Res. 2013 Apr;15(4):777-88. doi: 10.1093/ntr/nts175. Epub 2012 Sep 27. Review.

7.

Qualitative exploration of public and smoker understanding of, and reactions to, an endgame solution to the tobacco epidemic.

Edwards R, Peace J, Russell M, Gifford H, Thomson G, Wilson N.

BMC Public Health. 2012 Sep 13;12:782. doi: 10.1186/1471-2458-12-782.

8.

Use of emerging tobacco products in the United States.

McMillen R, Maduka J, Winickoff J.

J Environ Public Health. 2012;2012:989474. doi: 10.1155/2012/989474. Epub 2012 May 10.

9.

Non-cigarette tobacco products: what have we learnt and where are we headed?

O'Connor RJ.

Tob Control. 2012 Mar;21(2):181-90. doi: 10.1136/tobaccocontrol-2011-050281. Review.

10.

Daring to dream: reactions to tobacco endgame ideas among policy-makers, media and public health practitioners.

Edwards R, Russell M, Thomson G, Wilson N, Gifford H.

BMC Public Health. 2011 Jul 20;11:580. doi: 10.1186/1471-2458-11-580.

11.

Tobacco and nicotine product testing.

Hatsukami DK, Biener L, Leischow SJ, Zeller MR.

Nicotine Tob Res. 2012 Jan;14(1):7-17. doi: 10.1093/ntr/ntr027. Epub 2011 Apr 2. Review.

12.
13.

Clinical trials methods for evaluation of potential reduced exposure products.

Hatsukami DK, Hanson K, Briggs A, Parascandola M, Genkinger JM, O'Connor R, Shields PG.

Cancer Epidemiol Biomarkers Prev. 2009 Dec;18(12):3143-95. doi: 10.1158/1055-9965.EPI-09-0654. Review.

14.

Progressive commercial cigarette yield reduction: biochemical exposure and behavioral assessment.

Benowitz NL, Dains KM, Hall SM, Stewart S, Wilson M, Dempsey D, Jacob P 3rd.

Cancer Epidemiol Biomarkers Prev. 2009 Mar;18(3):876-83. doi: 10.1158/1055-9965.EPI-08-0731. Epub 2009 Mar 3.

15.

Developing the science base for reducing tobacco harm.

Hatsukami DK, Joseph AM, Lesage M, Jensen J, Murphy SE, Pentel PR, Kotlyar M, Borgida E, Le C, Hecht SS.

Nicotine Tob Res. 2007 Nov;9 Suppl 4:S537-53. doi: 10.1080/14622200701679040. Review.

16.

Introducing oral tobacco for tobacco harm reduction: what are the main obstacles?

Martinet Y, Bohadana A, Fagerström K.

Harm Reduct J. 2007 Nov 7;4:17.

17.

Angiogenesis and the role of the endothelial nicotinic acetylcholine receptor.

Cooke JP.

Life Sci. 2007 May 30;80(24-25):2347-51. Epub 2007 Feb 17. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk